Search company, investor...

Stage

Acquired | Acquired

About CARIS

CARIS is a developer of marine mapping software. Caris offers an effective solution for processing and robust quality control of sonar data and the creation and distribution of maps, charts, and, digital datasets. The CARIS Ping-To-Chart software is designed to deliver an integrated and seamless solution for the entire workflow of hydrographic information. CARIS offers a level of support with training sessions, consulting, and a series of courses as well as technical support via online services, multilingual telephone support, and email.

Headquarters Location

115 Waggoners Lane

Fredericton, New Brunswick, E3B 2L4,

Canada

506-458-8533

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo
You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo

CARIS Patents

CARIS has filed 104 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Molecular biology
  • Genetics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/3/2021

8/15/2023

Molecular biology, Genetics, NMDA receptor antagonists, Proteins, MGlu5 receptor antagonists

Grant

Application Date

2/3/2021

Grant Date

8/15/2023

Title

Related Topics

Molecular biology, Genetics, NMDA receptor antagonists, Proteins, MGlu5 receptor antagonists

Status

Grant

Latest CARIS News

Behind Career-Best Shooting, Caris LeVert Is Fitting In With The Cleveland Cavaliers

Mar 21, 2023

I cover the Cavs and Browns for Forbes. Got it! CLEVELAND, OHIO - MARCH 15: Caris LeVert #3 of the Cleveland Cavaliers shoots the ball during the ... [+] fourth quarter of the game against the Philadelphia 76ers at Rocket Mortgage Fieldhouse on March 15, 2023 in Cleveland, Ohio. The 76ers defeated the Cavaliers 118-109. NOTE TO USER: User expressly acknowledges and agrees that, by downloading and or using this photograph, User is consenting to the terms and conditions of the Getty Images License Agreement. (Photo by Jason Miller/Getty Images) Getty Images So far in his career, the best version of Caris LeVert came with him playing with the ball in his hands, creating looks for himself with a sprinkle of creation mixed in. He was a jitterbug, in-between operator likely best suited as a third ball handler. It’s the role he had in Brooklyn at least, where he ended up playing off of Kevin Durant and Kyrie Irving before he was sent out in the multi-team deal that sent James Harden to Houston. (And, coincidentally, Jarrett Allen to Cleveland.) The role LeVert has settled into with Cleveland is different. There are games where he is allowed to play the old way — think of his 41-point game against the Celtics earlier this season. But those are not common anymore. On a team with Darius Garland, Donovan Mitchell and an emerging Evan Mobley, makes sense. “He’s one of the guys that goes unsung at times,” said Cavs head coach J.B. Bickerstaff. “And he’s been willing to take a different role for this team than who he’s been. But again, he’s another guy who just wants to help the team win. He defends multiple positions for us. He’ll rebound. He just takes challenges. And he’s selfless in that way. Just all he wants to do is try to help us win, and he’ll do whatever it takes.” All season, even when it hasn’t always worked, LeVert has been willing to be malleable. On offense, that means taking catch-and-shoot threes. On defense, that means defending up against bigger threes because the Cavs lack a traditional big wing stopper. He’s also creating well, often slithering into the paint on a pick-and-roll when he does have the ball and finding Allen or another big on a dump off pass after he’s pulled the defense towards him. MORE FOR YOU “He’s raised his level,” said Donovan Mitchell. “I think his role is a little more consistent now, which is easier to find a groove. And you’re looking at it.” “I mean, it’s crazy to see how long he is and him deflecting basketballs and getting to the passing lanes,” said Darius Garland. “I mean, it’s crazy to see because he’s just so effective, and it really means a lot to us because he’s playing hard. We know that he can start on any team, but he’s taken a role that he’s started to get adjusted to, and he’s really excelling in it. So we love to see that from Vert, for sure.” LeVert’s catch-and-shoot numbers are the biggest change in his game. For the season, he’s shooting 38.4% on 2.8 catch-and-shoot threes per game. It’s built on last season, when he shot 40.8% on 1.8 catch-and-shoot threes per game. Before that, he’d only shot above 33% on catch-and-shoot threes in his career. "I think he understood, once the trade was made, where he was going to fit in and he put the time in to work on it. He's used to being the guy that has to create and create his own shot, so I think he did a great job of fitting in to what the team need is. And when you have the Donovan's and the Darius' of the world with the ball in their hand, a lot was going to come to him in catch-and-shoot opportunities, so I think he just prepared himself for that." This year, LeVert has also rebounded his shooting in season. In February, he shot 22.2% on catch-and-shoot threes. So far in March, he’s shooting 44.1%. It comes at a time when he is playing the best basketball he’s ever played with the Cavs. "I think I'm just getting more consistent with my looks,” LeVert said. “I think, obviously, your numbers will be more consistent when you kind of know where your shots are coming from and I think that's been a result of being healthy. I think, in years past, I've kind of missed games. This is the most games I've played since like my second year. Just being consistently on the court, knowing where your shots are going to come from, I think that has made a huge difference for me in my shooting numbers for sure." The playoffs might determine LeVert’s future. He’s in the last year of his contract and will hit unrestricted free agency in July. The Cavs don’t have an obvious way to replace him, so it’s likely they retain him on some sort of extension. And with the way LeVert is playing, and how he’s helping the Cavs win, he’s earning it. It could be a deal that is about rewarding him for his play more than just re-signing him so he doesn’t walk for nothing. “I’m just trying to be more locked in,” LeVert said after a recent game. “Playoff time coming and I know what that entails. I’ve been there a couple times, so I’m just trying to put myself in that mindset. My teammates give me a lot of confidence each and every night to just be myself, so they make it easy on me. “I feel pretty sharp. My handle feels sharp. My jump shot feels pretty sharp. My conditioning feels up to par. I’ve kind of kicked it into playoff mode.” Follow me on  Twitter . Check out my  website .

CARIS Frequently Asked Questions (FAQ)

  • Where is CARIS's headquarters?

    CARIS's headquarters is located at 115 Waggoners Lane, Fredericton.

  • What is CARIS's latest funding round?

    CARIS's latest funding round is Acquired.

  • Who are the investors of CARIS?

    Investors of CARIS include Teledyne Technologies.

  • Who are CARIS's competitors?

    Competitors of CARIS include Protean BioDiagnostics.

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Compare CARIS to Competitors

Tempus Logo
Tempus

Tempus builds a library of molecular and clinical data as well as a corresponding operating system for data accessibility. The company enables physicians to deliver personalized cancer care for patients through analytical and machine-learning platforms. It provides genomic sequencing services and molecular therapeutic data analysis to empower physicians to make real-time, data-driven decisions. It serves clients in the healthcare sector. It was formerly known as Tempus Consulting. The company was founded in 2015 and is based in Chicago, Illinois.

Protean BioDiagnostics Logo
Protean BioDiagnostics

Protean BioDiagnostics is committed to creating and deploying laboratory diagnostic tools to support physicians.

N
NeoGenomics Laboratories

NeoGenomics is a high-complexity CLIA–certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA, Tampa, FL and Fort Myers, FL. NeoGenomics services the needs of pathologists, oncologists, other clinicians and hospitals throughout the United States.

Natera Logo
Natera

Natera (NASDAQ: NTRA) operates as a clinical genetic testing company. It offers a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus as well as twin pregnancies for zygosity, a single-gene mutations screening test to identify single-gene disorders, carrier screening to determine carrier status for various genetic diseases, and more. The company was formerly known as Gene Security Network. The company was founded in 2004 and is based in Austin, Texas.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.